Quest Diagnostics vs Roivant Sciences

Quest Diagnostics (DGX), health care, and Roivant Sciences (ROIV), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Quest Diagnostics and Roivant Sciences are valued at about the same: $28.2B and $28B. Quest Diagnostics's operating margin in its latest fiscal year was 14.1% and Roivant Sciences's -6236%. Over the past year Quest Diagnostics's share price has moved +41.5% and Roivant Sciences's +88.2%.

Key facts

Quest Diagnostics market value
$28.2B
Roivant Sciences market value
$28B
Quest Diagnostics P/E
26.1
Quest Diagnostics revenue
$11BFY to 2025-12-31
Roivant Sciences revenue
$8.3MFY to 2026-03-31
Superinvestors holding both
0

Market values as of .

Quest Diagnostics vs Roivant Sciences: every measure side by side
Measure Quest Diagnostics Roivant Sciences
SectorHealth CareHealth Care
Country United States United Kingdom
Fiscal year ends2025-12-312026-03-31
Size
Market cap$28.2Bhigher$28Blower
Revenue$11Bhigher$8.3Mlower
Earnings$992Mhigher-$299.8Mlower
Employees60,000higher721lower
Total assets$16.2Bhigher$5.7Blower
Valuation
P/E26.1—
P/S2.6lower3396higher
P/B3.7—
Dividend yield1.29%—
Profitability
Operating margin14.1%higher-6236%lower
Balance sheet
Net assets$7.2Bhigher$4.5Blower
Total liabilities$8.9Bhigher$416.3Mlower
Total debt$5.7B—
Cash on hand$420Mlower$1.4Bhigher
Price change
Today-2.23%lower+0.26%higher
1 year+41.5%lower+88.2%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Quest Diagnostics only (3)

Percentages are each holding's share of that investor's reported portfolio. Who owns DGX · Who owns ROIV

Further comparisons

Learn

Questions and answers

Which is bigger, Quest Diagnostics or Roivant Sciences?

By market value, Quest Diagnostics is the larger: $28.2B against $28B for Roivant Sciences. By revenue in its latest fiscal year, Quest Diagnostics is the larger: $11B against $8.3M for Roivant Sciences.

Which has the higher operating margin?

Quest Diagnostics: 14.1%, against -6236% for Roivant Sciences. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Quest Diagnostics and Roivant Sciences?

None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Quest Diagnostics and 6 hold Roivant Sciences.

Cite this page

Funkfolio, “Quest Diagnostics vs Roivant Sciences”, data as of 18 November 2026. https://funkfolio.com/compare/dgx-vs-roiv

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.